文献速递MDS 与骨髓增殖性肿瘤白血病

Magrolimab联合阿扎胞苷治疗高危骨髓增生异常综合征患者:Ib期研究最终结果

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.
PubMed 文献 · J Clin Oncol · 2023-03-08

这项Ib期研究纳入95例未经治疗的高危骨髓增生异常综合征患者,接受Magrolimab联合阿扎胞苷治疗,完全缓解率为33%、总缓解率为75%,中位无进展生存期为11.6个月、中位总生存期未达到,在TP53突变患者中完全缓解率为40%、中位总生存期为16.3个月,耐受性良好。

要点

  • Magrolimab联合阿扎胞苷在未经治疗的高危骨髓增生异常综合征中完全缓解率33%、总缓解率75%。
  • TP53突变患者完全缓解率40%,中位总生存期16.3个月。
  • 34例(36%)接受异基因干细胞移植,2年总生存率77%。

核心结论

  • Magrolimab联合阿扎胞苷在未经治疗的高危骨髓增生异常综合征患者中耐受性良好且疗效有前景,包括TP53突变患者。
  • 一项Magrolimab/安慰剂联合阿扎胞苷的III期试验正在进行(ClinicalTrials.gov标识符:NCT04313881 [ENHANCE])。

研究设计与样本

  • Ib期研究,纳入95例未经治疗的修订版国际预后评分系统中间危/高危/极高危骨髓增生异常综合征患者。
  • Magrolimab静脉给药,起始剂量1 mg/kg,随后递增至30 mg/kg每周一次或每2周一次维持剂量。
  • 阿扎胞苷75 mg/m2静脉/皮下给药,每个28天周期第1-7天每日一次。
  • 主要终点为安全性和完全缓解率。

主要发现

  • 修订版国际预后评分系统风险为中间危/高危/极高危者分别占27%、52%、21%。
  • 59例(62%)具有不良细胞遗传学,25例(26%)具有TP53突变。
  • 最常见的治疗中出现的不良事件包括便秘(68%)、血小板减少(55%)和贫血(52%)。
  • 从基线至首次给药后评估的中位血红蛋白变化为-0.7 g/dL(范围,-3.1至+2.4)。
  • 完全缓解率和总缓解率分别为33%和75%,中位至缓解时间、完全缓解持续时间、总缓解持续时间和无进展生存期分别为1.9、11.1、9.8和11.6个月。

临床怎么用

  • 作者结论认为Magrolimab联合阿扎胞苷在未经治疗的高危骨髓增生异常综合征患者中耐受性良好且疗效有前景,包括TP53突变患者。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Magrolimab is a monoclonal antibody that blocks cluster of differentiation 47, a don't-eat-me signal overexpressed on cancer cells. Cluster of differentiation 47 blockade by magrolimab promotes macrophage-mediated phagocytosis of tumor cells and is synergistic with azacitidine, which increases expression of eat-me signals. We report final phase Ib data in patients with untreated higher-risk myelodysplastic syndromes (MDS) treated with magrolimab and azacitidine (ClinicalTrials.gov identifier: NCT03248479). PATIENTS AND METHODS: Patients with previously untreated Revised International Prognostic Scoring System intermediate-/high-/very high-risk MDS received magrolimab intravenously as a priming dose (1 mg/kg) followed by ramp-up to a 30 mg/kg once-weekly or once-every-2-week maintenance dose. Azacitidine 75 mg/m2 was administered intravenously/subcutaneously once daily on days 1-7 of each 28-day cycle. Primary end points were safety/tolerability and complete remission (CR) rate. RESULTS: Ninety-five patients were treated. Revised International Prognostic Scoring System risk was intermediate/high/very high in 27%, 52%, and 21%, respectively. Fifty-nine (62%) had poor-risk cytogenetics and 25 (26%) had TP53 mutation. The most common treatment-emergent adverse effects included constipation (68%), thrombocytopenia (55%), and anemia (52%). Median hemoglobin change from baseline to first postdose assessment was -0.7 g/dL (range, -3.1 to +2.4). CR rate and overall response rate were 33% and 75%, respectively. Median time to response, duration of CR, duration of overall response, and progression-free survival were 1.9, 11.1, 9.8, and 11.6 months, respectively. Median overall survival (OS) was not reached with 17.1-month follow-up. In TP53-mutant patients, 40% achieved CR with median OS of 16.3 months. Thirty-four patients (36%) had allogeneic stem-cell transplant with 77% 2-year OS. CONCLUSION: Magrolimab + azacitidine was well tolerated with promising efficacy in patients with untreated higher-risk MDS, including those with TP53 mutations. A phase III trial of magrolimab/placebo + azacitidine is ongoing (ClinicalTrials.gov identifier: NCT04313881 [ENHANCE]).

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Sallman DA, Al Malki MM, Asch AS, et al. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. J Clin Oncol. 2023. PMID: 36888930. doi:10.1200/JCO.22.01794

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。